vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and FONAR CORP (FONR). Click either name above to swap in a different company.
Expensify, Inc. is the larger business by last-quarter revenue ($35.2M vs $25.5M, roughly 1.4× FONAR CORP). On growth, FONAR CORP posted the faster year-over-year revenue change (2.4% vs -4.9%). Over the past eight quarters, Expensify, Inc.'s revenue compounded faster (2.4% CAGR vs -0.3%).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
FONAR Corp is a specialized medical technology firm that designs, manufactures, and distributes innovative MRI systems including upright and open models. It primarily serves U.S. hospitals, diagnostic imaging centers, and healthcare providers, delivering high-precision scanning solutions for clinical diagnostic use.
EXFY vs FONR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $25.5M |
| Net Profit | — | $2.1M |
| Gross Margin | 49.2% | — |
| Operating Margin | -11.2% | 13.5% |
| Net Margin | — | 8.0% |
| Revenue YoY | -4.9% | 2.4% |
| Net Profit YoY | — | 4.7% |
| EPS (diluted) | $-0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $25.5M | ||
| Q3 25 | $35.1M | $26.0M | ||
| Q2 25 | $35.8M | $27.3M | ||
| Q1 25 | $36.1M | $27.2M | ||
| Q4 24 | $37.0M | $24.9M | ||
| Q3 24 | $35.4M | $25.0M | ||
| Q2 24 | $33.3M | $25.9M | ||
| Q1 24 | $33.5M | $25.7M |
| Q4 25 | — | $2.1M | ||
| Q3 25 | $-2.3M | $2.3M | ||
| Q2 25 | $-8.8M | $729.3K | ||
| Q1 25 | $-3.2M | $2.5M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $-2.2M | $3.1M | ||
| Q2 24 | $-2.8M | $830.4K | ||
| Q1 24 | $-3.8M | $1.9M |
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.6% | — | ||
| Q4 24 | 51.0% | — | ||
| Q3 24 | 51.6% | — | ||
| Q2 24 | 56.9% | — | ||
| Q1 24 | 56.5% | — |
| Q4 25 | -11.2% | 13.5% | ||
| Q3 25 | -6.4% | 14.1% | ||
| Q2 25 | -28.9% | 5.3% | ||
| Q1 25 | -4.1% | 15.2% | ||
| Q4 24 | 1.3% | 11.9% | ||
| Q3 24 | 0.8% | 21.0% | ||
| Q2 24 | 0.7% | 7.4% | ||
| Q1 24 | -5.3% | 16.8% |
| Q4 25 | — | 8.0% | ||
| Q3 25 | -6.6% | 8.7% | ||
| Q2 25 | -24.6% | 2.7% | ||
| Q1 25 | -8.8% | 9.2% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | -6.2% | 12.6% | ||
| Q2 24 | -8.3% | 3.2% | ||
| Q1 24 | -11.3% | 7.3% |
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $121.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $132.7M | $176.9M |
| Total Assets | $186.0M | $217.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | $121.0K | ||
| Q3 25 | $61.5M | $122.0K | ||
| Q2 25 | $60.5M | $56.5M | ||
| Q1 25 | $59.6M | $123.0K | ||
| Q4 24 | $48.8M | $121.0K | ||
| Q3 24 | $39.2M | $136.0K | ||
| Q2 24 | $53.2M | $56.5M | ||
| Q1 24 | $49.3M | $134.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $66.9K | ||
| Q1 24 | — | — |
| Q4 25 | $132.7M | $176.9M | ||
| Q3 25 | $135.7M | $174.9M | ||
| Q2 25 | $131.8M | $172.6M | ||
| Q1 25 | $134.7M | $171.9M | ||
| Q4 24 | $128.2M | $169.8M | ||
| Q3 24 | $119.9M | $168.7M | ||
| Q2 24 | $114.0M | $166.0M | ||
| Q1 24 | $106.5M | $165.8M |
| Q4 25 | $186.0M | $217.2M | ||
| Q3 25 | $186.8M | $218.4M | ||
| Q2 25 | $187.1M | $216.9M | ||
| Q1 25 | $189.2M | $214.9M | ||
| Q4 24 | $173.7M | $208.0M | ||
| Q3 24 | $176.2M | $212.3M | ||
| Q2 24 | $192.9M | $214.2M | ||
| Q1 24 | $184.8M | $209.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $171.0K |
| Free Cash FlowOCF − Capex | — | $-227.0K |
| FCF MarginFCF / Revenue | — | -0.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | — | 0.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | $171.0K | ||
| Q3 25 | $4.2M | $1.7M | ||
| Q2 25 | $8.9M | $4.2M | ||
| Q1 25 | $4.8M | $3.1M | ||
| Q4 24 | $7.4M | $2.2M | ||
| Q3 24 | $3.7M | $1.7M | ||
| Q2 24 | $9.3M | $4.6M | ||
| Q1 24 | $3.5M | $2.8M |
| Q4 25 | — | $-227.0K | ||
| Q3 25 | — | $-177.0K | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-148.0K | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | -0.7% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 10.2% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.0% | 7.2% | ||
| Q2 24 | 0.0% | 1.6% | ||
| Q1 24 | 0.0% | 0.7% |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 5.79× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXFY
Segment breakdown not available.
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
